Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 239

1.

Self-crosslinked human serum albumin nanocarriers for systemic delivery of polymerized siRNA to tumors.

Son S, Song S, Lee SJ, Min S, Kim SA, Yhee JY, Huh MS, Chan Kwon I, Jeong SY, Byun Y, Kim SH, Kim K.

Biomaterials. 2013 Dec;34(37):9475-85. doi: 10.1016/j.biomaterials.2013.08.085. Epub 2013 Sep 16.

PMID:
24050874
2.

Biocompatible gelatin nanoparticles for tumor-targeted delivery of polymerized siRNA in tumor-bearing mice.

Lee SJ, Yhee JY, Kim SH, Kwon IC, Kim K.

J Control Release. 2013 Nov 28;172(1):358-66. doi: 10.1016/j.jconrel.2013.09.002. Epub 2013 Sep 10.

PMID:
24036198
3.

Tumor-targeting transferrin nanoparticles for systemic polymerized siRNA delivery in tumor-bearing mice.

Yhee JY, Lee SJ, Lee S, Song S, Min HS, Kang SW, Son S, Jeong SY, Kwon IC, Kim SH, Kim K.

Bioconjug Chem. 2013 Nov 20;24(11):1850-60. doi: 10.1021/bc400226b. Epub 2013 Oct 25.

PMID:
24107100
4.

Tumor-homing poly-siRNA/glycol chitosan self-cross-linked nanoparticles for systemic siRNA delivery in cancer treatment.

Lee SJ, Huh MS, Lee SY, Min S, Lee S, Koo H, Chu JU, Lee KE, Jeon H, Choi Y, Choi K, Byun Y, Jeong SY, Park K, Kim K, Kwon IC.

Angew Chem Int Ed Engl. 2012 Jul 16;51(29):7203-7. doi: 10.1002/anie.201201390. Epub 2012 Jun 13. Erratum in: Angew Chem Int Ed Engl. 2012 Nov 19;51(47):11661.

PMID:
22696263
5.

Bioreducible hyaluronic acid conjugates as siRNA carrier for tumor targeting.

Yoon HY, Kim HR, Saravanakumar G, Heo R, Chae SY, Um W, Kim K, Kwon IC, Lee JY, Lee DS, Park JC, Park JH.

J Control Release. 2013 Dec 28;172(3):653-61. doi: 10.1016/j.jconrel.2013.09.008. Epub 2013 Sep 17.

PMID:
24055507
6.

Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.

Höbel S, Koburger I, John M, Czubayko F, Hadwiger P, Vornlocher HP, Aigner A.

J Gene Med. 2010 Mar;12(3):287-300. doi: 10.1002/jgm.1431.

PMID:
20052738
7.

Cytoplasm-responsive nanocarriers conjugated with a functional cell-penetrating peptide for systemic siRNA delivery.

Tanaka K, Kanazawa T, Horiuchi S, Ando T, Sugawara K, Takashima Y, Seta Y, Okada H.

Int J Pharm. 2013 Oct 15;455(1-2):40-7. doi: 10.1016/j.ijpharm.2013.07.069. Epub 2013 Aug 1.

PMID:
23911914
8.

RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system.

Sakurai Y, Hatakeyama H, Sato Y, Hyodo M, Akita H, Ohga N, Hida K, Harashima H.

J Control Release. 2014 Jan 10;173:110-8. doi: 10.1016/j.jconrel.2013.10.003. Epub 2013 Oct 11.

PMID:
24120854
9.
10.

A study of the suppressive effect on human pancreatic adenocarcinoma cell proliferation and angiogenesis by stable plasmid-based siRNA silencing of c-Src gene expression.

Zhao X, Li DC, Zhao H, Li Z, Wang JX, Zhu DM, Zhou J, Cen JN.

Oncol Rep. 2012 Mar;27(3):628-36. doi: 10.3892/or.2011.1602. Epub 2011 Dec 21.

PMID:
22200682
11.

A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy.

Ding Y, Wang W, Feng M, Wang Y, Zhou J, Ding X, Zhou X, Liu C, Wang R, Zhang Q.

Biomaterials. 2012 Dec;33(34):8893-905. doi: 10.1016/j.biomaterials.2012.08.057. Epub 2012 Sep 12.

PMID:
22979990
12.

Direct cytosolic siRNA delivery by reconstituted high density lipoprotein for target-specific therapy of tumor angiogenesis.

Ding Y, Wang Y, Zhou J, Gu X, Wang W, Liu C, Bao X, Wang C, Li Y, Zhang Q.

Biomaterials. 2014 Aug;35(25):7214-27. doi: 10.1016/j.biomaterials.2014.05.009. Epub 2014 May 27.

PMID:
24875759
13.

Therapeutic delivery of siRNA silencing HIF-1 alpha with micellar nanoparticles inhibits hypoxic tumor growth.

Liu XQ, Xiong MH, Shu XT, Tang RZ, Wang J.

Mol Pharm. 2012 Oct 1;9(10):2863-74. Epub 2012 Sep 4.

PMID:
22924580
14.

Binary and ternary complexes based on polycaprolactone-graft-poly (N, N-dimethylaminoethyl methacrylate) for targeted siRNA delivery.

Huang Y, Lin D, Jiang Q, Zhang W, Guo S, Xiao P, Zheng S, Wang X, Chen H, Zhang HY, Deng L, Xing J, Du Q, Dong A, Liang Z.

Biomaterials. 2012 Jun;33(18):4653-64. doi: 10.1016/j.biomaterials.2012.02.052. Epub 2012 Apr 3.

PMID:
22480869
15.

In vivo delivery of small interfering RNA to tumors and their vasculature by novel dendritic nanocarriers.

Ofek P, Fischer W, Calderón M, Haag R, Satchi-Fainaro R.

FASEB J. 2010 Sep;24(9):3122-34. doi: 10.1096/fj.09-149641. Epub 2010 Apr 12.

PMID:
20385622
16.

A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics.

Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S, Muramatsu T.

Cancer Res. 2004 May 15;64(10):3365-70.

17.

The potential and advances in RNAi therapy: chemical and structural modifications of siRNA molecules and use of biocompatible nanocarriers.

Joo MK, Yhee JY, Kim SH, Kim K.

J Control Release. 2014 Nov 10;193:113-21. doi: 10.1016/j.jconrel.2014.05.030. Epub 2014 May 24. Review.

PMID:
24862319
18.

Pancreatic cancer therapy by systemic administration of VEGF siRNA contained in calcium phosphate/charge-conversional polymer hybrid nanoparticles.

Pittella F, Miyata K, Maeda Y, Suma T, Watanabe S, Chen Q, Christie RJ, Osada K, Nishiyama N, Kataoka K.

J Control Release. 2012 Aug 10;161(3):868-74. doi: 10.1016/j.jconrel.2012.05.005. Epub 2012 May 11.

PMID:
22580114
19.

Co-delivery of anti-vascular endothelial growth factor siRNA and doxorubicin by multifunctional polymeric micelle for tumor growth suppression.

Huang HY, Kuo WT, Chou MJ, Huang YY.

J Biomed Mater Res A. 2011 Jun 1;97(3):330-8. doi: 10.1002/jbm.a.33055. Epub 2011 Apr 4.

PMID:
21465641
20.

Oral delivery of shRNA and siRNA via multifunctional polymeric nanoparticles for synergistic cancer therapy.

Han L, Tang C, Yin C.

Biomaterials. 2014 May;35(15):4589-600. doi: 10.1016/j.biomaterials.2014.02.027. Epub 2014 Mar 6.

PMID:
24613049

Supplemental Content

Support Center